Blog
RSS FeedPosted by Michael Wonder on 23 Jan 2023
ICER publishes final evidence report on fezolinetant for vasomotor symptoms associated with menopause
23 January 2023 - Independent appraisal committee voted that evidence is not yet adequate to demonstrate a net health benefit ...
Posted by Michael Wonder on 13 Jan 2023
Public Summary Documents – September 2022 PBAC meeting
13 January 2023 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the September 2022 PBAC ...
Posted by Michael Wonder on 22 Dec 2022
ICER publishes final evidence report on gene therapies for haemophilia A and B
22 December 2022 - Fair pricing benchmarks suggest upper bounds for price of Roctavian at approximately $1.9 million and for Hemgenix ...
Posted by Michael Wonder on 22 Dec 2022
Final report for the post-market review of medicines for smoking cessation and review outcomes
22 December 2022 - The final report for the post-market review of medicines for smoking cessation is now available. The ...
Posted by Michael Wonder on 21 Dec 2022
ICER publishes evidence report on treatments for multiple sclerosis
21 December 2022 - Evidence is rated as insufficient to differentiate the net health benefit between ublituximab and other monoclonal antibodies; ...
Posted by Michael Wonder on 21 Dec 2022
PBS Expenditure and Prescriptions Report (2021-22)
21 December 2022 - The PBS Expenditure and Prescriptions Report 1 July 2021 to 30 June 2022 is now available. ...
Posted by Michael Wonder on 01 Dec 2022
ICER publishes evidence report on fezolinetant for vasomotor symptoms associated with menopause
1 December 2022 - Evidence is rated as promising but inconclusive to determine whether fezolinetant provides a net health benefit for ...
Posted by Michael Wonder on 18 Nov 2022
PBAC Public Summary Document (November 2022)
18 November 2022 - The Public Summary Documents for the Review of the base-case discount rate in the PBAC Guidelines from ...
Posted by Michael Wonder on 11 Nov 2022
Public Summary Documents (first time decisions not to recommend and deferrals) - July 2022 PBAC meeting
11 November 2022 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the July 2022 PBAC ...
Posted by Michael Wonder on 03 Nov 2022
Outcome statement - September 2022 DUSC meeting
3 November 2022 - The outcome statement from the September 2022 DUSC meeting is now available. ...
Posted by Michael Wonder on 28 Oct 2022
Public Summary Documents – July 2022 PBAC meeting
28 October 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the July 2022 PBAC ...
Posted by Michael Wonder on 25 Oct 2022
DUSC utilisation analysis public release documents (October 2022)
25 October 2022 - The utilisation analysis public release documents from the June 2022 DUSC meeting are now available. ...
Posted by Michael Wonder on 20 Oct 2022
ICER publishes final evidence report and policy recommendations on treatments for obesity management
20 October 2022 - Independent appraisal committee voted that evidence is adequate to demonstrate that semaglutide provides a net health benefit ...
Posted by Michael Wonder on 17 Oct 2022
ICER releases draft evidence report on treatments for multiple sclerosis
17 October 2022 - Public comment period now open until 11 November 2022; requests to make oral comment during public ...
Posted by Michael Wonder on 13 Oct 2022
HARmonized protocol template to enhance reproducibility of hypothesis evaluating real world evidence studies on treatment effects: a good practices report of a joint ISPE/ISPOR Task Force
12 October 2022 - Ambiguity in communication of key study parameters limits the utility of real-world evidence studies in health care ...